GSK Q3 Core Earnings Beat, but Shingrix Sales Weaken
J.P. Morgan analysts say GSK’s third-quarter core earnings beat expectations, largely due to cost timing, while Shingrix sales were weaker than expected. Quarterly turnover was 1% ahead.
GSK's third-quarter core earnings beat expectations, but this was largely driven by the timing of costs, so investors might focus instead on weaker-than-expected sales of shingles vaccine Shingrix, analysts at J.P. Morgan say in a research note. The U.K. drugmaker's quarterly turnover was 1% ahead…